Determination of Stomach Soluble and Foaming Rabeprazole and Metronidazole Tablets Formulation (original) (raw)

EXPERIMENTAL & CLINICAL MEDICINE GEORGIA, 2022

Abstract

Since the discovery of Helicobacter pylori, numerous studies have been performed on its effective eradication, both in vitro and in vivo. Proton pump inhibitors, antibiotics of different groups, their modified drug form, etc. were tested. However, studies confirm that using these remedies does not achieve the desired pharmacotherapeutic effect. Foams - are light systems, have a large touch surface, completely cover the mucous membrane and penetrate into it. Concentrated solutions are not taken at the place of foam formation, which does not cause irritation of the mucous membrane. Characterized with high bioavailability and rapid therapeutic effect. The aim of the study was to determine the targeted delivery of H. pylori's eradication "gold standard" ingredients - rabeprazole and metronidazole, gastric soluble and foaming tablets. Taking into account the physico-chemical and technological properties of the active pharmaceutical ingredients, excipients are selected, their quantitative ratios are established, and the composition of rabeprazole and metronidazole foaming and gastric-soluble tablets is determined. Rabeprazole stomach-soluble and foaming tablets were prepared by direct compression with the use of excipients, including the antacid sodium bicarbonate, and metronidazole with the classic wet granulation. Keywords: Helicobacter pylori, Rabeprazole, Metronidazole, Foaming tablets

Dali Berashvili hasn't uploaded this paper.

Let Dali know you want this paper to be uploaded.

Ask for this paper to be uploaded.